2010∼2025年間全球糖尿病市場 是由出版商Visiongain在2010年03月所出版的。
這份英文市場調查報告書包含152 Pages 價格從美金2331起跳。
2009年全球治療糖尿病市場總值超過250億美金，與過去相比有大幅的成長。
本報告包含：檢視全球糖尿病市場、販售預測與市場分配、研究開發管道，並以SWOT分析法(強弱機危綜合分析法)分析業界動態，加上專門學者的見解，以下記概要向您呈現。
第1章 執行摘要
第2章 介紹糖尿病及其治療方式
- 所謂的糖尿病
- 對健康的影響：造成心臟、腎臓、眼睛、神經等損傷
- 糖尿病的主要危險因素：肥胖
- 糖尿病的其他危險因素：年齡、遺傳、人種
- 診斷：檢查準則將會有所改變
- 罹患率：糖尿病罹患率持續增加
- 糖尿病的經濟成本：美國--580億美金
- 治療方法
- 不適切的糖尿病治療高達20∼90%
第3章 2010∼2025年之全球糖尿病市場
- 全球糖尿病市場：2009年
- 全球糖尿病市場：2010∼2025年
- 抗糖尿病藥物治療類別的銷售預測：2010∼2025年
第4章 人胰島素及類胰島素之市場前景(2010∼2025年)
第5章 其他治療糖尿病藥物之市場前景(2010∼2025年)
- 糖尿病口服產品
- Byetta/Exenatide LAR
第6章 對糖尿病市場的有利及不利因素
第7章 治療糖尿病藥物之各國市場(2010∼2025年)
- 主要國家市場：2009年
- 先進國家市場：2010∼2025年
- 新興經濟市場：2010∼2025年
第8章 研究開發管道
第9章 專門學者訪談
第10章 結論
圖表
Abstract
How will the diabetes market develop, with rising disease prevalence in many
countries?
In 2009, the diabetes treatment market generated worldwide sales of over $25
billion, with strong growth from the previous year. The incidence and
prevalence of diabetes mellitus are on the rise worldwide, in line with
lifestyle changes and ageing populations. In particular, the increasing
prevalence of diabetes is closely linked with that of obesity, creating
significant market opportunities in developed nations and some developing
countries. The World Health Organization estimates the number of diabetics to
exceed 350 million by 2030. Governments and other healthcare providers around
the world are investing heavily in prevention and treatment of this serious -
but controllable - disorder.
As our new report - World Diabetes Market Analysis 2010-2025 - shows, the
diabetes market is one of the most important sectors in the pharmaceutical
industry. All segments of the diabetes therapy market have been expanding, but
which will grow fastest in years to come? What are the main therapeutic and
commercial trends to watch? How will the principal national markets perform
from 2010 to 2025? What will happen to the current leading products/therapies?
How does diabetes overlap with obesity? This report covers those and other
crucial questions, providing the information that you need.
Success in the diabetes treatment market from 2010 onwards will be
characterised by the launch of products with superior performance. This report
shows how emerging technologies that increase clinical effectiveness,
tolerability and ease of use will be important therapeutically and
commercially.
Detailed analysis of the global diabetes market
World Diabetes Market Analysis 2010-2025 examines that sector through a
comprehensive review of information sources. We harness both primary and
secondary research. This report provides unique sales forecasts, market share
analyses, discussions of R&D pipeline developments and analyses of commercial
drivers and restraints, including a SWOT analysis. There are over 75 tables
and figures included, as well as three full interviews with relevant
authorities. The result is a comprehensive market- and industry-centred study,
with detailed analyses and informed opinion to benefit your work.
Why you should buy World Diabetes Market Analysis 2010-2025
This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for
anti-diabetes drugs from 2010 to 2025, including predicted revenues, growth
rates and other metrics for leading products
- You will receive an overall forecast for the global diabetes treatment
market from 2010 to 2025, as well as those for main drug classes, with
comprehensive discussions and other supporting information
- You will find out where the market is heading - both technologically and
commercially - from 2010 onwards
- You will receive sales forecasts for the leading national markets from
2010 to 2025 (US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and
India)
- You will identify key R&D pipeline developments and up-and-coming products
- You will discover the drivers, restraints, competition and opportunities
influencing the diabetic treatment sector, including insulins and oral
anti-diabetics classes
- You will investigate under-met needs in that sector, with both therapeutic
requirements and commercial opportunities discussed
- You will discover expert views from our survey, including full interview
transcripts.
- You can obtain this report today
Table of Contents
1. Executive Summary
- 1.1 The Diabetes Market Trajectory
- 1.1.1 Visiongain' s Prediction for Total Diabetes Sales in 2025
- 1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for
Pharmaceuticals is Growing
- 1.1.3 Diabetes Care Works: The Market will Expand Significantly
- 1.1.4 Awareness, Advocacy and Government Spending Aimed at Diabetes are
all Expanding
- 1.2 Aims, Scope and Format of the Report
- 1.3 Research and Analysis Methods
2. Introduction to Diabetes and its Treatment
- 2.1 What is Diabetes Mellitus?
- 2.1.1 Symptoms of Diabetes
- 2.1.2 Type 1 Diabetes
- 2.1.3 Type 2 Diabetes
- 2.1.4 Gestational Diabetes
- 2.1.5 Other Types of Diabetes
- 2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic
Syndrome
- 2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve
Damage
- 2.2.1 Heart Problems
- 2.2.2 Kidney Damage
- 2.2.3 Blindness
- 2.2.4 Neuropathy
- 2.2.5 Amputation
- 2.2.6 Ketoacidosis, Coma, and Death
- 2.3 Obesity: The Major Diabetes Risk Factor
- 2.4 Other Risk Factors: Age, Genetics, Race
- 2.4.1 Type 2 Diabetes Risk Increases with Age
- 2.4.2 Obesity Increases Chances of Type 2 Diabetes
- 2.4.3 Genetic Factors
- 2.4.4 Type 1 Diabetes: Genetics vs. Environment
- 2.4.5 Family History
- 2.4.6 Ethnicity
- 2.5 Diagnosis: Guidelines are Subject to Change
- 2.6 Prevalence: Diabetes Rates are Rising Epidemically
- 2.7 The Economic Costs of Diabetes: $58 billion in the US
- 2.8 Treatments
- 2.8.1 Insulin: a Central Therapeutic Product
- 2.8.2 Medications
- 2.8.3 More Novel Therapies? A New Discovery about how Insulin Works May
Lead to New Drugs
- 2.9 Diabetes Treatment Noncompliance Rates 25% to 90%
3. The World Diabetes Drug Market, 2010-2025
- 3.1 The World Diabetes Drug Market in 2009
- 3.1.1 Human Insulins & Analogues had Largest Market Share in 2009
- 3.1.2 Top Twenty Anti-Diabetic Brands, 2009
- 3.2 The World Diabetes Drug Market Forecast, 2010-2025
- 3.3 Anti-Diabetic Pharmaceutical Therapeutic Category Sales Forecasts,
2010-2025
- 3.3.1 Two Therapeutic Categories will Power Growth from 2010-2016
- 3.3.2 Human Insulins and Analogues will Continue to Drive Growth from
2017-2025
4. Human Insulins and Analogues: Market Prospects, 2010-2025
- 4.1 Leading Human Insulins and Analogues
- 4.1.1 Lantus - Commercial Prospects
- 4.1.2 Novorapid - Commercial Prospects
- 4.1.3 Humalog - Commercial Prospects
- 4.1.4 Novomix - Commercial Prospects
- 4.1.5 Levemir - Commercial Prospects
- 4.1.6 Actraphane HM - Commercial Prospects
5. Other Anti-Diabetic Agents: Market Prospects, 2010-2025
- 5.1 Leading Oral Anti-Diabetic Products
- 5.1.1 Actos - Commercial Prospects
- 5.1.2 Avandia: How will Sales Fare After 2013?
- 5.1.3 Avandamet - Commercial Prospects
- 5.1.4 Januvia - Commercial Prospects
- 5.2 Byetta/Exenatide LAR: Potentially Revolutionary Non-Insulin Injection
Blockbuster
- 5.2.1 Byetta' s Strengths
- 5.2.2 Restraints on Byetta
6. Drivers and Restraints in the Diabetes Drug Market
- 6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Work
- 6.1.1 Diabetes is Chronic
- 6.1.2 Younger Patients, More-Comprehensive Diagnoses
- 6.1.3 Prevention is Inadequate
- 6.1.4 Drugs Often Used in Combination
- 6.2 Weaknesses
- 6.2.1 Diagnostic Inadequacies
- 6.2.2 Developing Countries Cannot Afford Many Drugs
- 6.2.3 Noncompliance Rates up to 65%
- 6.3 Opportunities
- 6.3.1 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
- 6.3.2 The Greying of the World Population
- 6.3.3 Obesity: A Major Contributing Factor for Type 2 Diabetes
- 6.3.4 Expanding Markets: India and China
- 6.3.5 Changing Guidelines for Defining Diabetes
- 6.3.6 Techniques for Increasing Patient Compliance
- 6.3.7 Novel Drugs, Novel Delivery Methods
- 6.4 Threats
- 6.4.1 The Most-Significant Threat: Changes in Drug Approval Guidelines
- 6.4.2 Changing FDA Guidelines for New Drug Approvals
- 6.4.3 Generic Erosion of Branded Drug Sales
- 6.4.4 Vaccine to Prevent Type 1 Diabetes?
- 6.4.5 Diabetes Drugs' Side Effects
7. Antidiabetic Drugs: Leading Country Markets, 2010-2025
- 7.1 Leading Anti-Diabetic Pharmaceutical Country Markets, 2009
- 7.2 Leading Developed Country Anti-Diabetic Pharmaceutical Markets,
2010-2025
- 7.2.1 The US Anti-Diabetic Pharmaceutical Market
- 7.2.2 The Japanese Anti-Diabetic Pharmaceutical Market
- 7.2.3 European Diabetes Pharmaceutical Markets
- 7.3 Emerging Economy Anti-Diabetic Pharmaceutical Market Forecasts,
2010-2025
- 7.3.1 Anti-Diabetic Pharmaceuticals are Making the Leap to Developing
Countries
- 7.3.2 The Chinese Anti-Diabetic Pharmaceutical Market
- 7.3.3 The Indian Anti-Diabetic Pharmaceutical Market
8. The R&D Pipeline for Diabetes Treatments
- 8.1 The Anti-Diabetic Drugs Pharmaceutical Pipeline
- 8.2 The Human Insulins and Analogues Pipeline
- 8.2.1 Technosphere Insulin (Mankind)
- 8.2.2 VIAject/VIAdel (Biodel)
- 8.2.3 CKD 401(Chong Kun Dang)
- 8.2.4 BHT 3021/RG 7426 (Bayhill Therapeutics/Genentech)
- 8.2.5 Nasulin/CPE-215 (CPEX Pharmaceuticals)
- 8.2.6 Capsulin (Diabetology)
- 8.2.7 ORMD 0801 (Oramed)
- 8.2.8 TPM 02/Insulin (Phosphagenics)
- 8.2.9 IN 105 (Biocon)
- 8.2.10 NN 1250 (Novo Nordisk)
- 8.2.11 NN 5401 (Novo Nordisk)
- 8.2.12 SBS 1000 (SemBioSys)
- 8.3 The Glitazone Anti-Diabetics Pipeline
- 8.3.1 ACTOplus met XR (Takeda)
- 8.3.2 Balaglitazone/DRF 2593 (Dr Reddy' s/Nordic Bioscience)
- 8.3.3 MK 0431C (Merck & Co)
- 8.3.4 MSDC 0160 (Metabolic Solutions Development)
- 8.3.5 Lobeglitazone/CKD 501 (Chong Kun Dang)
- 8.4 DPP-IV Inhibitor Anti-Diabetics Pipeline
- 8.4.1 SYR 322 (Takeda)
- 8.4.2 Alogliptin (Takeda)
- 8.4.3 Linagliptin/BI 1356 BS (Boehringer Ingelheim)
- 8.4.4 Dutogliptin/PHX 1149 (Phenomix)
- 8.4.5 LC 15 0444 (LG Life Sciences)
- 8.4.6 Saxagliptin and Metformin Combination
- 8.4.7 MK 0431C (Merck & Co)
- 8.4.8 SK 0403 (Sanwa Kagaku/ Kowa/ Choongwae)
- 8.4.9 Teneligliptin/MP 513 (Mitsubishi Tanabe Pharma)
- 8.4.10 ALS 20426/AMG 222 (Amgen)
- 8.4.11 Carmegliptin/R 1579 (Roche)
- 8.4.12 KRP 104 (Kyorin)
- 8.4.13 Melogliptin/GRC 8200 (Glenmark)
- 8.4.14 SYR 472 (Takeda)
- 8.4.15 TA 6666 (Mitsubishi Tanabe Pharma)
- 8.5 Sulphonylurea and Biguanide Anti-Diabetics Pipeline
- 8.5.1 NCT00660907/Dapagliflozin + Metformin Combination (AstraZeneca)
- 8.5.2 Metformin XL (Flamel Technologies)
- 8.5.3 Metcontrol (Generex Biotechnology)
- 8.6 Alpha-glucosidase Inhibitor Anti-Diabetics Pipeline
- 8.6.1 KMV 0207 (Kissei/Takeda)
- 8.6.2 PharmaLinks Compounds (University of Strathclyde)
- 8.7 Miscellaneous Class of Anti-Diabetic Drugs in the R&D Pipeline
- 8.7.1 Byetta LAR/AC 2993 LAR (Amylin/Alkermes/Eli Lilly)
- 8.7.2 Albiglutide/GSK 716155 (GlaxoSmithKline)
- 8.7.3 Lixisenatide/ZP 10/AVE 0010 (sanofi-aventis)
- 8.7.4 LY 2189265 (Eli Lilly)
- 8.7.5 Taspoglutide/ BIM 51077 (Roche)
- 8.7.6 ITCA 650 (Intarcia)
- 8.7.7 Gosogliptin/PF 734200 (Pfizer)
- 8 7.8 Semaglutide/NN 9535 (Novo Nordisk)
- 8.7.9 Bromocriptine/Cycloset (VeroScience/ S2 Therapeutics)
- 8.7.10 SF 1019/R-1818 (Argyll Biotechnologies)
- 8.7.11 Arhalofenate/MBX 102 (Metabolex and Ortho-McNeil)
- 8.7.12 Canagliflozin/TA 7284 (Mitsubishi Tanabe Pharma/ Johnson &
Johnson)
- 8.7.13 Dapagliflozin (Bristol-Myers Squibb)
- 8.7.14 DiaPep277 (Andromeda/ DeveloGen)
- 8.7.15 Mirabegron/YM 178 (Astellas)
- 8.7.16 Otelixizumab/TRX 4/ChAglyCD3 (GlaxoSmithKline/Tolerx/BTG)
- 8.7.17 Teplizumab/MGA 031 (MacroGenics/Eli Lilly)
- 8.7.18 DIAMYD/GAD65 (Diamyd Medical)
9. Expert Views from Key Opinion Leaders
- 9.1 Prof. R. Keith Campbell, Pharm.B., MBA, CDE Distinguished Professor in
Diabetes Care, Department of Pharmacotherapy, College of Pharmacy, Washington
State University, WA, US
- 9.1.1 Key Unmet Needs
- 9.1.2 About Research and Development
- 9.1.3 Problems with the Current Use of Anti-Diabetic Treatments
- 9.1.4 Challenges in the Development of Anti-Diabetic Drugs
- 9.1.5 Complexities Involved in Developing New Anti-Diabetic Drugs
- 9.1.6 Technologies and Strategies for Discovery of New Anti-Diabetic
Agents
- 9.1.7 Growth Opportunities in Diabetes Market
- 9.1.8 Challenges Facing the Diabetes Pharmaceutical Industry
- 9.1.9 Main Regions Offering Growth Potential Worldwide
- 9.1.10 Pipeline Developments from a Physician' s Perspective
- 9.1.11 Prospects of Replacing Current Drugs and Treatments
- 9.2 Interview with Dr Fred Levine, M.D., Ph.D. Professor, Burnham
Institute for Medical Research; Director, Sanford Children' s Health Research
Center, La Jolla, California, US
- 9.2.1 On Alternative Delivery Methods
- 9.2.2 On Cardiovascular Problems Associated with Oral Anti-Diabetics
- 9.2.3 On Obesity and Diabetes
- 9.2.4 On Byetta
- 9.2.5 On Stem Cell Therapy/Cure
- 9.3 Interview with Bjorn Tyrberg, PhD., Associate Professor, Metabolic
Signaling & Disease, Diabetes and Obesity Research Center, Burnham Institute
for Medical Research, La Jolla, CA, US
- 9.3.1 On Diet and Diabetes
- 9.3.2 On The Link Between Obesity and Diabetes
- 9.3.3 On Byetta and Liraglutide
10. Conclusions: Diabetes is a Growth Market with Significant Opportunities
- 10.1 Diabetes Increasing Worldwide: 2-14% Prevalence Rate
- 10.2 World Diabetes Market: A Growing Opportunity
- 10.3 Oral Anti-Diabetics Sales vs. Insulins Sales
List of Tables
- Table 2.1 Diabetes Numbers (in Millions), by WHO Region, 2000 & 2030
- Table 2.2 Secondary Costs of Diabetes in the US, 2007
- Table 2.3 Total Costs of Diabetes to Africa: $4.2 Billion, 2007
- Table 2.4 Diabetes World Market Sales, 2009
- Table 2.5 Insulin Types by Onset Rate, 2010
- Table 2.6 Alternative Delivery Methods in the R&D Pipeline by Type and
Development Stage, 2010
- Table 2.7 Anti-Diabetic Drugs by Class, 2010
- Table 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
- Table 3.2 Top Twenty Diabetes Pharmaceutical Brands, 2009
- Table 3.3 World Diabetes Pharmaceutical Market Sales Forecast, 2010-2016
- Table 3.4 World Diabetes Pharmaceutical Market Sales Forecast, 2017-2025
- Table 3.5 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts,
2010-2016
- Table 3.6 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts,
2017-2025
- Table 4.1 Lantus Sales Forecast, 2010-2016
- Table 4.2 Lantus Sales Forecast, 2017-2025
- Table 4.3 Novorapid Sales Forecast, 2010-2016
- Table 4.4 Novorapid Sales Forecast, 2017-2025
- Table 4.5 Humalog Sales Forecast, 2010-2016
- Table 4.6 Humalog Sales Forecast, 2017-2025
- Table 4.7 Novomix Sales Forecast, 2010-2016
- Table 4.8 Novomix Sales Forecast, 2017-2025
- Table 4.9 Levemir Sales Forecast, 2010-2016
- Table 4.10 Levemir Sales Forecast, 2017-2025
- Table 4.11 Actraphane HM Sales Forecast, 2010-2016
- Table 4.12 Actraphane HM Sales Forecast, 2017-2025
- Table 5.1 Actos Sales Forecast, 2010-2016
- Table 5.2 Actos Sales Forecast, 2017-2025
- Table 5.3 Avandia Sales Forecast, 2010-2016
- Table 5.4 Avandia Sales Forecast, 2017-2025
- Table 5.5 Avandamet Sales Forecast, 2010-2016
- Table 5.6 Avandamet Sales Forecast, 2017-2025
- Table 5.7 Junuvia Sales Forecast, 2010-2016
- Table 5.8 Junuvia Sales Forecast, 2017-2025
- Table 5.9 Byetta Sales Forecast, 2010-2016
- Table 5.10 Byetta Sales Forecast, 2017-2025
- Table 6.1 SWOT Analysis for World Diabetes Market: Strengths & Weaknesses,
2010-2025
- Table 6.2 SWOT Analysis for World Diabetes Market: Opportunities &
Threats, 2010-2025
- Table 6.3 Recent FDA Guidance on the Cardiovascular Risk of Diabetes Drugs
- Table 7.1 Leading Diabetes Drugs: Country Markets, 2009
- Table 7.2 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts,
2010-2016
- Table 7.3 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts,
2017-2025
- Table 8.1 Key Drugs in the Human Insulins and Analogues R&D Pipeline, 2009
- Table 8.2 Key Drugs in the Glitazone Anti-Diabetics R&D Pipeline, 2009
- Table 8.3 Key Drugs in the DPP-IV Inhibitor Anti-Diabetics R&D Pipeline,
2009
- Table 8.4 Key Drugs in the Sulphonylurea and Biguanide Anti-Diabetics R&D
Pipeline, 2009
- Table 8.5 Key Drugs in the Alpha-Glucosidase Inhibitor Anti-Diabetics R&D
Pipeline, 2009
- Table 8.6 Key Drugs in the Miscellaneous Class R&D Pipeline, 2009
List of Figures
- Figure 2.1 Rise in Diabetes Cases (in Millions), by WHO Region, 2000 & 2030
- Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007
- Figure 2.3 Secondary Costs of Diabetes in Africa, 2007
- Figure 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
- Figure 3.2 World Diabetes Pharmaceutical Market Sales Forecasts, 2010-2016
- Figure 3.3 World Diabetes Pharmaceutical Market Sales Forecasts, 2017-2025
- Figure 3.4 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
- Figure 3.5 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2015
- Figure 3.6 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2020
- Figure 3.7 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2025
- Figure 3.8 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts,
2010-2025
- Figure 4.1 Lantus Sales Forecast, 2010-2025
- Figure 4.2 Novorapid Sales Forecast, 2010-2025
- Figure 4.3 Humalog Sales Forecast, 2010-2025
- Figure 4.4 Novomix Sales Forecast, 2010-2025
- Figure 4.5 Levemir Sales Forecast, 2010-2025
- Figure 4.6 Actraphane HM Sales Forecast, 2010-2025
- Figure 5.1 Actos HM Sales Forecast, 2010-2025
- Figure 5.2 Avandia Sales Forecast, 2010-2025
- Figure 5.3 Avandamet Sales Forecast, 2010-2025
- Figure 5.4 Junuvia Sales Forecast, 2010-2025
- Figure 5.5 Byetta Sales Forecast, 2010-2025
- Figure 6.1 Global Population Aged Over 65 Years, 2010-2025
- Figure 6.2 Population Aged 65 Years or Over in Major Anti-Diabetic
Pharmaceutical Country Markets, 2009 and 2025
- Figure 6.3 Prevalence of Diabetes Worldwide in Major Anti-Diabetic
Pharmaceutical Country Markets, 2000 and 2030
- Figure 6.4 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007
and 2030
- Figure 7.1 Leading Anti-Diabetic Drugs: Country Market Shares, 2009
- Figure 7.2 Leading Anti-Diabetic Drugs: Country Market Shares, 2015
- Figure 7.3 Leading Anti-Diabetic Drugs: Country Market Shares, 2020
- Figure 7.4 Leading Anti-Diabetic Drugs: Country Market Shares, 2025
- Figure 7.5 US and Japanese Anti-Diabetic Drugs: Market Sales Forecasts,
2010-2025
- Figure 7.6 European, Chinese, Indian and Brazilian Anti-Diabetic Drugs:
Market Sales Forecasts, 2010-2025
Companies Listed
- Abbott Laboratories Ltd.
- ActivX
- Alkermes, Inc.
- Altea Therapeutics Corp.
- American Diabetes Association (ADA)
- Amgen Inc.
- Amylin Pharmaceuticals, Inc.
- Andromeda Biotech (a subsidiary of Clal Biotechnology Industries)
- Astellas Pharma Inc.
- AstraZeneca plc.
- Argyll Biotechnologies, LLC
- Axcess Ltd.
- Battelle Medical Device Solutions
- Baxter International Inc.
- Bayhill Therapeutics Inc.
- Biocon Ltd.
- Biodel Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Pharmaceuticals
- BTG plc
- Center for Biotechnology and Genomic Medicine, Medical College of Georgia,
US
- Chiesi Ltd.
- Chong Kun Dang Pharmaceutical Corp.
- Choongwae Pharma Corp.
- College of Pharmacy, Washington State University, WA, US
- CPEX Pharmaceuticals, Inc.
- DeveloGen AG
- Diabetology Ltd.
- Diamyd Medical AB
- Diabetes and Obesity Research Center, Burnham Institute for Medical
Research, La Jolla, CA, US
- DPT Laboratories Ltd.
- Dong Sung Industrial Co., Ltd.
- Dr. Reddy' s Laboratories Ltd.
- Eli Lilly and Company Limited
- European Medicines Agency (EMEA)
- European Patent Convention
- Emisphere Technologies, Inc.
- Ergo Sciences Inc.
- Forest Laboratories, Inc.
- Flamel Technologies, Inc.
- Food and Drug Administration (FDA) [US]
- Garvan Institute of Medical Research, Sydney, Australia
- Galenix Pharma and Galenix Inc.
- Genentech Inc.
- Generex Biotechnology Corp.
- GlaxoSmithKline plc (GSK)
- Glenmark Pharmaceuticals Ltd.
- Human Genome Sciences, Inc.
- Intarcia Therapeutics, Inc.
- International Diabetes Federation (IDF)
- Immunosyn Corporation
- Ipsen Ltd.
- Johnson & Johnson Inc.
- Kissei Pharmaceutical Co, Ltd.
- Kowa Company Ltd.
- KYORIN Pharmaceutical Co., Ltd.
- LG Life Sciences Ltd.
- Lifescan UK (Ortho Clinical Diagnostics Ltd.)
- MacroGenics
- MannKind Corp.
- Merck & Co., Inc.
- Metabolic Solutions Development Co.
- Metabolex Inc.
- Mitsubishi Tanabe Pharma Corp.
- Nordic Bioscience A/S.
- Novartis AG.
- Novo Nordisk A/S.
- Oramed Pharmaceuticals Inc.
- Ortho-McNeil-Janssen Pharmaceuticals, Inc
- PDL BioPharma Inc.
- Pfizer Inc.
- PharmaLinks
- Phenomix Corp.
- Phosphagenics Ltd.
- Proxima Concepts Ltd.
- Qdose Ltd.
- Roche Holdings AG.
- Royal Adelaide Hospital, Adelaide, Australia
- S2 Therapeutics Inc.
- Sanford Children' s Health Research Center, La Jolla, California, US
- sanofi-aventis
- Sanford Children' s Health Research Center, La Jolla, California, US
- Sanwa Kagaku Kenkyusho Co., Ltd.
- SemBioSys Genetics Inc.
- Servier Laboratories
- Takeda Pharmaceuticals Co. Ltd.
- Teijin Pharma Limited
- Teva Pharmaceutical Industries Ltd.
- Tolerance Therapeutics
- Tolerx, Inc.
- The National Diabetes Information Clearinghouse
- University of California at Los Angeles (UCLA), US
- University of Strathclyde, Glasgow, UK
- VeroScience LLC.
- Washington State University, WA, US
- Watson Pharmaceuticals, Inc.
- World Diabetes Congress of the International Diabetic Federation
- World Health Organisation (WHO)
- Yeda Research and Development Company Ltd.
- Ypsomed Holding AG.
- Zealand Pharma A/S
|
